The first patient with thalassemia in the phase 1 clinical trial of BRL-101 product was cured and discharged from the hospital
2023-02-17
BRL Medicine’s world's first non-viral PD1 - CAR-T product " BRL-201 " obtained IND approval from CDE
2022-12-14
Lead the world! BRL Medicine's new generation of Quikin CAR-T research results published in Nature
2022-09-01
BRL Medicine's β-Thalassemia Gene Therapy " BRL-101 " obtained IND approval from CDE
2022-08-16
Nature Medicine article states that BRL-101 gene therapy for thalassemia has cured children for over 2 years
2022-08-04
2022 Future Healthcare VB100｜BRL Medicine awarded as
2022-06-16
